MCRB
Seres Therapeutics, Inc. · Healthcare · Market cap $22.9M
Insiders sold $2K net in the last 90 days ·4 sellers, 0 buyers· 4 of 4 sales under Rule 10b5-1 plans· latest Form 4 filed Aug 18, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$55K
reported sales (SEC code S)
Unique Insiders
5
in the rolling window
Latest filing
Aug 18, 2026
Brady Kelly
Seres Therapeutics, Inc. (MCRB) has 16 SEC Form 4 filings (38 transaction rows) in the rolling window, disclosed by 5 distinct insiders. Most recent filing: Aug 18, 2026.
Inside the rolling window, 5 insiders at Seres Therapeutics, Inc. reported no open-market purchases and 16 open-market sales totaling $55K. The most active filer is Director Shaff Eric D. with 4 filings. The most recent open-market filing is a sale of 64 shares by See Remarks Brady Kelly, dated Aug 17, 2026, worth $291.
- Industry:Biotechnology
- CEO:Richard N. Kender
- Employees:66
- HQ:Cambridge, MA, US
- IPO:2015-06-26
| Source | |||||||
|---|---|---|---|---|---|---|---|
Brady KellyFirst in 3 months | See Remarks | Sale | 64 | $291 | Aug 18 | -47.0% | SEC ↗ |
Shaff Eric D.First in 3 months | Director | Sale | 263 | $1K | Aug 18 | -47.0% | SEC ↗ |
Henn Matthew RFirst in 3 months | See Remarks | Sale | 81 | $369 | Aug 18 | -47.0% | SEC ↗ |
DesRosier ThomasFirst in 3 months | See Remarks | Sale | 82 | $373 | Aug 18 | -47.0% | SEC ↗ |
Henn Matthew RFirst in 3 months | See Remarks | Sale | 77 | $580 | May 19 | -69.1% | SEC ↗ |
DesRosier ThomasFirst in 3 months | See Remarks | Sale | 79 | $595 | May 19 | -69.1% | SEC ↗ |
Shaff Eric D.First in 3 months | Director | Sale | 259 | $2K | May 19 | -69.1% | SEC ↗ |
Brady KellyFirst filing | See Remarks | Sale | 59 | $444 | May 19 | -69.1% | SEC ↗ |
Shaff Eric D.First in 3 months | Director | Sale | 259 | $2K | Feb 18 | -72.1% | SEC ↗ |
Young Teresa L.First in 3 months | See Remarks | Sale | 75 | $635 | Feb 18 | -72.1% | SEC ↗ |
DesRosier ThomasFirst in 3 months | See Remarks | Sale | 78 | $661 | Feb 18 | — | SEC ↗ |
Henn Matthew RFirst in 3 months | See Remarks | Sale | 89 | $754 | Feb 18 | — | SEC ↗ |
Henn Matthew RFirst filing | See Remarks | Sale | 1,257 | $22K | Nov 18 | — | SEC ↗ |
Young Teresa L.First filing | See Remarks | Sale | 1,042 | $18K | Nov 18 | — | SEC ↗ |
DesRosier ThomasFirst filing | See Remarks | Sale | 76 | $1K | Nov 18 | — | SEC ↗ |
Shaff Eric D.First filing | Director | Sale | 217 | $4K | Nov 18 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does MCRB have?
Seres Therapeutics, Inc. (MCRB) has 16 SEC Form 4 filings (38 transaction rows) in the rolling 365-day window, disclosed by 5 distinct insiders. Most recent filing: Aug 18, 2026.
When was the most recent SEC Form 4 filing for MCRB?
The most recent Form 4 filing for MCRB on Tracefour is dated Aug 18, 2026.
Who is the most active insider at MCRB?
The most active SEC Form 4 filer at MCRB in the rolling window is Director Shaff Eric D., with 4 filings.
What is the net insider flow at MCRB over the last 6 months?
Over the trailing 180 days, insiders at MCRB have net sold $6K based on SEC Form 4 disclosures.
What is the total insider buy and sell value at MCRB in the current window?
Inside the rolling window, insiders at MCRB bought $0 and sold $55K based on SEC Form 4 filings.
Can I get alerts for MCRB insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Seres Therapeutics, Inc. (MCRB). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Seres Therapeutics, Inc. is in the Healthcare sector.